资源描述：
《large bcell lymphoma current standards of 弥漫性大b细胞淋巴瘤的现行标准课件》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、MultimodalityConferenceDiffuseLargeB-CellLymphoma:CurrentStandardsofCareandClinicalAdvancesAlirezaAbdolmohammadi,MDHem/OncFellow-102/17/2011ChristopherR.Flowers,MD,MSDirector,LymphomaProgramMedicalDirector,OncologyDataCenterAssistantProfessor,BoneMarrowandS
2、temCellTransplantation DepartmentofHematologyandOncology EmoryUniversity Atlanta,GeorgiaDiffuseLargeB-CellLymphoma:CurrentStandardsofCareandClinicalAdvancesThisprogramissupportedbyaneducationalgrantfromImage:3D4Medical.com/Copyright©2010GettyImages,Inc.AllR
3、ightsReserved.AboutTheseSlidesOurthankstothepresenterswhogavepermissiontoincludetheiroriginaldataUsersareencouragedtousetheseslidesintheirownnoncommercialpresentations,butweaskthatcontentandattributionnotbechanged.UsersareaskedtohonorthisintentTheseslidesma
4、ynotbepublishedorpostedonlinewithoutpermissionfromClinicalCareOptionsDisclaimerThematerialspublishedontheClinicalCareOptionsWebsitereflecttheviewsoftheauthorsofthe CCOmaterial,notthoseofClinicalCareOptions,LLC,theCMEproviders,orthecompaniesprovidingeducatio
5、nalgrants.ThematerialsmaydiscussusesanddosagesfortherapeuticproductsthathavenotbeenapprovedbytheUnitedStatesFoodandDrugAdministration.Aqualifiedhealthcareprofessionalshouldbeconsultedbeforeusinganytherapeuticproductdiscussed.Readersshouldverifyallinformatio
6、nanddatabeforetreatingpatientsorusinganytherapiesdescribedinthesematerials.DiffuseLargeB-CellLymphomaOverviewandmolecularbiologyCurrenttreatmentapproachesLocalizedDLBCLAdvanced-stageDLBCLNovelapproachesandongoingclinicaltrialsDiffuseLargeB-CellLymphomaMostc
7、ommonNHL:31%Peakincidencein6thdecadeCurablein50%ormoreofcasesMediansurvival:wkstomosif nottreatedClinicaloutcomesandmolecular featureshighlyheterogeneousLargecellswithlossoffolliculararchitectureofnode30%to40%presentwithrapidlyenlarging,symptomaticmasswithB
8、symptomsMaypresentasextranodaldisease(stomach,CNS,testis,skin)MichalletAS,etal.BloodRev.2009;23:11-23.DLBCL:PrognosticFactorsRiskGroupRiskFactors,nCR,%5-YrOS,%Patients(allages)Low0-18773Lowintermediate
